365 related articles for article (PubMed ID: 24966606)
1. Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease.
Blaslov K; Bulum T; Zibar K; Duvnjak L
World J Gastroenterol; 2014 Jun; 20(23):7356-65. PubMed ID: 24966606
[TBL] [Abstract][Full Text] [Related]
2. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.
Liu Y; Wei R; Hong TP
World J Gastroenterol; 2014 Jul; 20(27):9090-7. PubMed ID: 25083081
[TBL] [Abstract][Full Text] [Related]
3. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Carbone LJ; Angus PW; Yeomans ND
J Gastroenterol Hepatol; 2016 Jan; 31(1):23-31. PubMed ID: 26111358
[TBL] [Abstract][Full Text] [Related]
4. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.
Wang XC; Gusdon AM; Liu H; Qu S
World J Gastroenterol; 2014 Oct; 20(40):14821-30. PubMed ID: 25356042
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
Ohki T; Isogawa A; Toda N; Tagawa K
Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
[TBL] [Abstract][Full Text] [Related]
6. The role of incretin hormones and glucagon in patients with liver disease.
Junker AE
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.
Scheen AJ
Clin Pharmacokinet; 2014 Sep; 53(9):773-85. PubMed ID: 25091053
[TBL] [Abstract][Full Text] [Related]
8. Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.
Li CL; Zhao LJ; Zhou XL; Wu HX; Zhao JJ
J Huazhong Univ Sci Technolog Med Sci; 2015 Jun; 35(3):333-336. PubMed ID: 26072069
[TBL] [Abstract][Full Text] [Related]
9. Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease.
Nakouti T; Karagiannis AK; Tziomalos K; Cholongitas E
Curr Vasc Pharmacol; 2015; 13(5):649-57. PubMed ID: 25412688
[TBL] [Abstract][Full Text] [Related]
10. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Deacon CF
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
[TBL] [Abstract][Full Text] [Related]
11. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
12. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
13. Incretin-based therapies: where will we be 50 years from now?
Meier JJ; Nauck MA
Diabetologia; 2015 Aug; 58(8):1745-50. PubMed ID: 25994073
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.
Makri E; Kita M; Goulas A; Papaioannidou P; Efstathiadou ZA; Adamidou F; Polyzos SA
Diabetes Metab Syndr; 2020; 14(6):1913-1919. PubMed ID: 33011499
[TBL] [Abstract][Full Text] [Related]
15. Potential of incretin-based therapies for non-alcoholic fatty liver disease.
Samson SL; Bajaj M
J Diabetes Complications; 2013; 27(4):401-6. PubMed ID: 23352496
[TBL] [Abstract][Full Text] [Related]
16. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
17. Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis.
Kovalic AJ; Satapathy SK; Chalasani N
Hepatol Int; 2018 Mar; 12(2):97-106. PubMed ID: 29600430
[TBL] [Abstract][Full Text] [Related]
18. Is there a place for incretin therapies in obesity and prediabetes?
Holst JJ; Deacon CF
Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
[TBL] [Abstract][Full Text] [Related]
19. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
20. Physiology and pathophysiology of incretins in the kidney.
von Websky K; Reichetzeder C; Hocher B
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
